This site is intended for healthcare professionals only
Date of publication:
Investigators wanted to analyse the risk of cardiovascular (CV) events and mortality in patients with type 2 diabetes mellitus in relation to how well they adhered to lipid-lowering medications. They analysed 12,914 patients with type 2 diabetes from across 1363 healthcare centres in Sweden. Patients started on lipid-lowering therapy during a 3-year period were followed from their first prescription until they had a first CV event. Compared with high-adherent patients, low-adherent primary prevention patients showed a higher risk of all outcomes including a doubling for all-cause mortality.
Sign up to all DiabetesontheNet journals